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        Vascular endothelial growth factor (VEGF; also 
termed VEGF-A) is a member of a growing 
family of related proteins that include VEGF-B, 
-C, and -D, and placental growth factor (PlGF; 
for review see reference   1  ). VEGF/vascular 
permeability factor was fi  rst identifi  ed and char-
acterized by Senger et al. as a potent stimulator 
of endothelial permeability (  2  ). VEGF was sub-
sequently reported to promote proliferation, 
migration, and survival of endothelial cells (  3  ). 
In addition, VEGF has been implicated in in-
fl  ammatory processes, including rheumatoid ar-
thritis, cancer, and infl  ammatory bowel disease 
(  4  –  6  ). Several studies have demonstrated in-
creased VEGF levels in animal and human mod-
els of sepsis (  7  –  11  ). Importantly, inhibition of 
VEGF signaling with soluble Flt-1 (sFlt-1) or 
antibodies against Flk-1 improved morbidity and 
mortality in septic mice (  7, 11  ). 
  PlGF occurs in four isoforms in humans 
(PlGF-1  –  4), and in one isoform in mice (PlGF-2) 
(  12  –  15  ). PlGF was originally identifi  ed in the pla-
centa (  13, 16  ) but has subsequently been shown 
to be expressed in other tissues, including the 
heart, lung, thyroid gland, and skeletal muscle 
(for review see reference   17  ). Circulating levels 
of PlGF are normally undetectable. However, in-
creased PlGF levels have been described in several 
conditions, including cancer (  18  –  20  ), cutaneous 
wound and bone fracture healing (  21  –  24  ), ath-
erosclerosis, and sickle cell disease (  25  ). Recently, 
we demonstrated that circulating levels of PlGF 
are elevated in mouse and human models of sep-
sis (  7  ). Previous studies have implicated a role for 
PlGF in infl  ammation (  21, 23, 25  –  31  ). Thus, we 
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  Recently, we demonstrated that circulating levels of vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF) are increased in sepsis (Yano, K., P.C. Liaw, J.M. 
Mullington, S.C. Shih, H. Okada, N. Bodyak, P.M. Kang, L. Toltl, B. Belikoff, J. Buras, et al. 
2006.   J. Exp. Med.   203:1447  –  1458). Moreover, enhanced VEGF/Flk-1 signaling was shown 
to contribute to sepsis morbidity and mortality. We tested the hypothesis that PlGF also 
contributes to sepsis outcome. In mouse models of endotoxemia and cecal ligation punc-
ture, the genetic absence of PlGF or the systemic administration of neutralizing anti-PlGF 
antibodies resulted in higher mortality compared with wild-type or immunoglobulin 
G  –  injected controls, respectively. The increased mortality associated with genetic defi  ciency 
of PlGF was reversed by adenovirus (Ad)-mediated overexpression of PlGF. In the endotoxemia 
model, PlGF defi  ciency was associated with elevated circulating levels of VEGF, induction of 
VEGF expression in the liver, impaired cardiac function, and organ-specifi  c accentuation of 
barrier dysfunction and infl  ammation. Mortality of endotoxemic PlGF-defi  cient mice was 
increased by Ad-mediated overexpression of VEGF and was blocked by expression of soluble 
Flt-1. Collectively, these data suggest that up-regulation of PlGF in sepsis is an adaptive 
host response that exerts its benefi  t, at least in part, by attenuating VEGF signaling. 
© 2008 Yano et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
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cecal ligation puncture (CLP) (  7  ). The PlGF      /      mice used in 
this study were backcrossed to an FVB background. Previous 
studies have demonstrated strain-specifi   c sensitivity to LPS 
(  32  –  34  ). Thus, we wished to confi  rm these fi  ndings in FVB 
mice. The i.p. administration of 18 mg/kg LPS resulted in a 
time-dependent increase in plasma PlGF concentrations, with 
peak levels (3,447.4 pg/ml) occurring at 24 h (  Fig. 1 A  ).   Simi-
larly, in a CLP model of sepsis, peak levels of PlGF (111.4 pg/ml) 
occurred at 24 h (  Fig. 1 A  ). Previously, we demonstrated that 
PlGF protein levels were increased in all tissues examined, 
hypothesized that elevated levels of PlGF in sepsis might con-
tribute (as do increased VEGF levels) to the pathophysiology of 
the host response to infection. On the contrary, we found that 
PlGF protects against sepsis morbidity and mortality. 
    RESULTS   
  PlGF protein and mRNA levels are induced in animal models 
of sepsis 
  We recently demonstrated that circulating PlGF levels are in-
creased in C57BL/6 mice injected with LPS or subjected to 
    Figure 1.         PlGF levels in sepsis and survival studies in PlGF-defi  cient mice.   (A, a) Plasma levels of PlGF in wild-type male FVB mice injected i.p. with 18 mg/kg 
LPS at the time points indicated. (b) Same as in a but in a CLP mouse model. (B) Shown are results of quantitative real-time analyses (mRNA copy number per 10  6  
copies of 18S) of PlGF in organs from male FVB mice at various time points after i.p. injection with 18 mg/kg LPS. (C) In situ hybridization (ISH) and immunohis-
tochemistry (IHC) for PlGF in the heart, lung, and liver of male FVB mice treated in the absence (nontreated) or presence of 18 mg/kg LPS at 12 h. The insets in d, 
h, and i show a higher magnifi  cation of a representative area from each fi  eld. Arrows indicate PlGF signal. Bar: 50   μ  m; (insets) 25   μ  m. (D, a) Survival curves for 
male PLGF  +/+   (wild-type, WT) or PLGF     /     (knockout, KO) mice injected i.p. with 18 mg/kg LPS. (b) Survival curves for female PLGF  +/+   (WT) or PLGF     /     (KO)  mice 
injected i.p. with 18 mg/kg LPS. (c) Survival curves for wild-type male mice pretreated with anti-PlGF antibody (PlGF ab) or IgG (CTL ab) and injected i.p. with 
18 mg/kg LPS. (d) Survival curves for male PLGF  +/+   (WT) or PLGF     /     (KO) mice subjected to CLP. (e) Survival curves for female PLGF  +/+   (WT) or PLGF     /     (KO)  mice 
subjected to CLP. (f) Survival curves for wild-type male mice pretreated with anti-PlGF antibody (PlGF ab) or IgG (CTL ab) and subjected to CLP. Data in A and B 
are expressed as means + SD of at least three independent experiments. *, P   <   0.05; **, P   <   0.01; and ***, P   <   0.0001 compared with no treatment (0 h time point).     JEM VOL. 205, October 27, 2008 
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including the brain, lung, heart, liver, kidney, and spleen (  7  ). In 
real-time PCR assays, there was a time-dependent induction of 
PlGF transcripts at 24 h in the brain (5.3-fold), lung (14.3-
fold), liver (28-fold), kidney (25.7-fold), and spleen (8.5-fold). 
PlGF mRNA levels in the heart peaked at 6 h (54.2-fold;   Fig. 
1 B  ). In situ hybridization and immunohistochemical studies 
revealed a PlGF signal in perivascular cells but not the endothe-
lium (  Fig. 1 C   shows the heart, lung, and liver). Collectively, 
these fi  ndings suggest that sepsis is associated with the wide-
spread induction of PlGF mRNA and protein expression. 
  PlGF defi  ciency is associated with increased sepsis mortality 
  We next wished to determine whether PlGF contributes to 
sepsis outcome. To that end, 10  –  12-wk-old PlGF      /      mice 
or wild-type littermates were administered 18 mg/kg LPS or 
subjected to CLP. PlGF defi  ciency was associated with sig-
nifi  cantly lower survival rate in both the endotoxemia model 
(wild-type male, 62.5% vs. PlGF      /      male, 11.8%; wild-type 
female, 56.3% vs. PlGF      /      female, 12.5%) and in CLP (wild-
type male, 50% vs. PlGF      /      male, 0%; wild-type female, 50% vs. 
    Figure 2.         Effect of PlGF defi  ciency on tissue and/or circulating lev-
els of PlGF, VEGF, sFlt-1, and IL-6.   (A,  a – d)  PLGF +/+   (WT) or PLGF     /     (KO) 
male mice were injected i.p. with or without 16 mg/kg LPS. Blood samples 
were taken 24 h later and assayed for plasma levels of free PlGF, free VEGF, 
sFlt-1, and IL-6. (e  –  h) Same as in a  –  d, except that wild-type mice were pre-
treated with anti-PlGF antibody (Pab) or IgG (CTL) and injected i.p. with or 
without 16 mg/kg LPS. (B) PLGF  +/+   (WT) or PLGF     /     male mice were injected 
i.p. with or without 16 mg/kg LPS. Mouse organs were assayed for VEGF 
protein levels by ELISA at the time points indicated. Data are expressed as 
means + SD of three independent experiments. *, P   <   0.05; **, P   <   0.01; and 
***, P   <   0.0001 compared with the respective untreated controls (and where 
indicated between LPS-treated PlGF-defi  cient and wild-type mice).    
    Figure 3.         Effect of PlGF defi  ciency on cardiac function 
and vascular permeability in a mouse model of endotoxemia.  
(A, a and b) PLGF  +/+   (WT) or PLGF     /     (KO) male mice were injected i.p. 
with or without 16 mg/kg LPS and were subjected to echocardiogram 
and electrocardiogram 24 h later. Shown are quantitative analyses for 
heart rate (HR) and fractional shortening (FS). (c and d) Same as in a 
and b except that wild-type mice were pretreated with anti-PlGF antibody 
(Pab) or IgG (CTL) and injected i.p. with or without 16 mg/kg LPS. 
(B, a) PLGF  +/+   (WT, W) or PLGF     /     (KO, K) male mice were injected i.p. 
with or without 16 mg/kg LPS. 24 h later, the animals were injected i.v. 
with 0.1 ml 1% Evans blue dye. After 40 min, the mice were perfused, 
and the brain, lung, heart, liver, kidney, and spleen were harvested and 
incubated in formamide for 3 d to elute Evans blue dye. Shown is the 
quantitation of Evans blue extravasation (OD = 620 nm). (b) Same as 
in a except that wild-type mice were pretreated with anti-PlGF anti-
body (PlGF ab, P) or IgG (CTL IgG, C) and injected i.p. with or without 
16 mg/kg LPS. Data are expressed as means + SD of three independent 
experiments. *, P   <   0.05; and **, P   <   0.01 compared with the respective 
untreated controls (and where indicated between PlGF-defi  cient and 
wild-type mice).     2626 P  L  GF AND SEPSIS   | Yano et al. 
    Figure 4.         Effect of PlGF defi  ciency on tissue mRNA/protein levels of infl  ammatory and hemostatic markers in a mouse model of endo-
toxemia.   PLGF +/+   (WT) or PLGF     /     (KO) male mice were injected i.p. with or without 16 mg/kg LPS. (A) Shown are the results of quantitative real-time 
PCR analyses (mRNA copy number per 10  6   copies of 18S) of ICAM-1, VCAM-1, E-selectin, P-selectin, COX-2, and PAI-1 in the heart, lung and liver at 
24 h. Data are expressed as means + SD of three independent experiments. *, P   <   0.05; **, P   <   0.01; and ***, P   <   0.0001 compared with untreated controls JEM VOL. 205, October 27, 2008 
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PlGF      /      female, 0%;   Fig. 1 D  ). The diff  erences in survival 
between wild-type male and female FVB mice were not statis-
tically signifi  cant. Interestingly, the increased mortality associ-
ated with the genetic defi  ciency of PlGF was less pronounced 
in younger mice (6 wk old; unpublished data). To test for the 
eff  ect of acute PlGF down-regulation in the adult animal, FVB 
mice were administered 1 mg of neutralizing monoclonal anti-
PlGF antibody (clone 5D11D4) i.p. 20 h before initiation 
of sepsis. In these experiments, PlGF levels in the plasma were 
undetectable (see   Fig. 2 A  ). In 10  –  12-wk-old male mice, anti-
PlGF antibody  –  mediated depletion of PlGF resulted in reduced 
sepsis survival in LPS-treated mice (control IgG, 62.5% vs. 
PlGF antibody, 12.5%) and mice subjected to CLP (control 
IgG, 50% vs. PlGF antibody, 0%;   Fig. 1 D  ). Similar results were 
obtained in female mice and in younger animals (6 wk old; un-
published data). Thus, PlGF has a protective role in sepsis. 
  PlGF defi  ciency is associated with increased VEGF levels 
in sepsis 
  We previously demonstrated that endotoxemia in mice is asso-
ciated with increased circulating levels of VEGF, sFlt-1, and 
the infl  ammatory marker IL-6 (  7  ). In this study, there were no 
diff  erences in baseline plasma levels of VEGF, sFlt-1, or IL-6 in 
PlGF-defi  cient mice versus wild-type controls (  Fig. 2  ).   As ex-
pected, PlGF levels were undetectable under all conditions in 
PlGF      /      mice and antibody-treated animals (  Fig. 2 A  , a and e). 
In response to 16 mg/kg LPS, PlGF      /      mice demonstrated 
signifi  cantly higher plasma levels of VEGF (2.6-fold) and IL-6 
(2.4-fold) compared with wild-type controls (  Fig. 2 A  , b and d). 
The dose of 16 mg/kg LPS was chosen for these and subse-
quent morbidity experiments because 18 mg/kg LPS led to 
nearly 100% mortality (  Fig. 1  ). A similar eff  ect was observed in 
PlGF antibody  –  treated animals compared with IgG  –  injected 
controls (VEGF, 3-fold; IL-6, 1.7-fold;   Fig. 2 A  , f and h). 
In contrast, PlGF defi  ciency did not infl  uence endotoxemia-
mediated induction of sFlt-1 (  Fig. 2 A  , c and g). In wild-type 
mice, endotoxemia was associated with reduced VEGF protein 
levels in the lung at 6 h, and in the lung and brain at 24 h, and 
with increased VEGF protein levels in the liver and kidney at 
6 h and in the spleen at 24 h (  Fig. 2 B  ). Compared with wild-
type mice, PlGF      /      mice demonstrated signifi  cantly higher 
levels of VEGF protein and mRNA in the liver at 24 h. Thus, 
PlGF defi  ciency results in increased circulating levels of VEGF 
and sustained induction of VEGF expression in the liver. 
  PlGF defi  ciency is associated with increased 
endotoxemia-mediated cardiac dysfunction 
and barrier dysfunction 
  Consistent with our previous results (  7  ), systemic administra-
tion of LPS or CLP in mice resulted in marked depression of 
cardiac function, as indicated by reduced fractional shortening 
and heart rate on echocardiography (  Fig. 3 A  ).   The eff  ect of 
endotoxin on fractional shortening was accentuated in PlGF      /      
mice (  Fig. 3 A  , b) and in wild-type mice administered PlGF 
antibody (  Fig. 3 A  , d). Endotoxemic-associated bradycardia 
was accentuated by PlGF antibody (  Fig. 3 A  , c). PlGF defi  -
ciency was also associated with an accentuation of barrier dys-
function. Compared with wild-type mice, LPS administration 
in PlGF      /      mice resulted in increased extravasation of Evans 
blue dye in the liver and spleen (  Fig. 3 B  , a). Antibody-mediated 
depletion of PlGF resulted in increased extravasation occur-
ring in the lung, liver, and kidney (  Fig. 3 B  , b). Collectively, 
these fi  ndings suggest that PlGF defi  ciency is associated with 
impaired cardiac function and organ-specifi  c accentuation of 
vascular permeability during sepsis. 
  PlGF defi  ciency results in altered endotoxemia-mediated 
expression of infl  ammatory and coagulation mediators 
  Compared with wild-type controls, endotoxemic PlGF      /      mice 
demonstrated signifi  cant vascular bed  –  specifi  c changes in the 
expression of infl  ammatory and procoagulant molecules (  Fig. 4  ; 
and Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20080398/DC1).   Specifi  cally, PlGF defi  ciency re-
sulted in increased expression of intercellular adhesion mole-
cule (ICAM)  –  1 in the heart (1.9-fold), lung (1.7-fold), liver 
(6.5-fold), kidney (2.7-fold), and spleen (1.4-fold); increased 
expression of vascular cell adhesion molecule (VCAM)  –  1 in 
the liver (2.9-fold); increased E-selectin expression in the heart 
(2.8-fold) and liver (6.9-fold) but decreased E-selectin expres-
sion in the lung (0.5-fold); increased P-selectin expression in the 
lung (1.5-fold) and liver (3.7-fold); increased cyclooxygenase 
(COX)-2 expression in the heart (2.9-fold), liver (47.5-fold), 
kidney (5.7-fold), and spleen (4.5-fold); and increased plasmino-
gen activator inhibitor (PAI)  –  1 in the liver (5.3-fold) and de-
creased PAI-1 in the heart (0.3-fold), brain (0.3-fold), kidney 
(0.6-fold), and spleen (0.3-fold;   Fig. 4 A   and Fig. S1). 
  Immunofl   uorescent studies were used to determine the 
localization of the mediators described in the previous paragraph 
in the liver, heart, and lung. In the wild-type liver, LPS resulted 
in increased expression of ICAM-1 and P-selectin in endothelial 
cells of the sinusoids and veins (  Fig. 4 B  , a and d), and PAI-1 in 
sinusoidal endothelial cells alone (  Fig. 4 B  , f). LPS appeared to 
result in a slight induction of VCAM-1 in venular endothelial 
cells (  Fig. 4 B  , b) and of E-selectin in sinusoidal and venular en-
dothelial cells (  Fig. 4 B  , c). COX-2 was induced in occasional 
CD31-negative cells (  Fig. 4 B  , e). LPS injection of PlGF      /      
mice resulted in the further induction of ICAM-1 and P-selec-
tin in sinusoidal and venular endothelium (  Fig. 4 B  , a and d), 
increased expression of VCAM-1 in both endothelial cell popu-
lations (  Fig. 4 B  , b), increased expression of E-selectin and PAI-1, 
(and where indicated between PlGF-defi  cient and wild-type mice). (B) Double immunofl  uorescence staining for activation markers and CD31 in the 
liver of wild-type mice treated in the absence (WT) or presence of 16 mg/kg LPS (WT/L) and PlGF     /     mice treated with 16 mg/kg LPS (PKO/L) at 24 h. 
(a) ICAM-1 (green) and CD31 (red). (b) VCAM-1 (green) and CD31 (red). (c) E-selectin (green) and CD31 (red). (d) P-selectin (green) and CD31 (red). 
(e) COX-2 (red) and CD31 (green). (f) PAI-1 (red) and CD31 (green). Bars: 132   μ  m; (insets) 42   μ  m.     
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signifi  cantly greater myeloperoxidase (MPO) activity in the 
liver of PlGF      /      versus wild-type controls (  Fig. 5 B  ). Consis-
tent with these latter fi  ndings, CD45 staining demonstrated 
increased leukocyte infi  ltration in the liver of PlGF      /      com-
pared with wild-type endotoxemic mice (  Fig. 5 C  ). In con-
trast to the fi  ndings in the liver, MPO activity in the lung did 
not diff  er between endotoxemia wild-type and PlGF      /      
mice (unpublished data). 
  Excess mortality in endotoxemic PlGF-defi  cient mice is 
accentuated by overexpression of VEGF and rescued 
by overexpression of sFlt-1 
  The increased mortality in endotoxemic PlGF      /      mice was 
rescued by overexpression of PlGF (  Fig. 6 A  ).   However, the 
particularly in sinusoidal endothelial cells (  Fig. 4 B  , c and f), 
and increased expression of COX-2 in CD31-negative 
cells (  Fig. 4 B  , e). Larger images of the liver data are shown 
in Fig. S2 (A and B; available at http://www.jem.org/cgi/
content/full/jem.20080398/DC1). 
  In the heart of LPS-treated wild-type mice, ICAM-1, 
VCAM-1, E-selectin, and P-selectin were induced in capil-
lary and venular endothelium, whereas COX-2 and PAI-1 
were slightly increased in CD31-negative cells (Fig. S2, 
C and D). In PlGF      /      mice, LPS administration resulted in 
increased endothelial expression of ICAM-1 and E-selectin 
but not VCAM-1 or P-selectin. Endotoxemic PlGF      /      mice 
demonstrated increased expression of COX-2 and decreased 
expression of PAI-1 in CD31-negative endothelial cells. 
  In the lung, LPS injection of wild-type mice resulted in 
increased expression of ICAM-1 and P-selectin in venular 
and capillary endothelium and possibly in parenchymal cells 
(Fig. S2, E and F). VCAM-1 and E-selectin were increased 
primarily in venular endothelium. COX-2 was increased 
in CD31-negative cells on the luminal side of venular endo-
thelium. PAI-1 was slightly induced, primarily in venous 
endothelial cells. In PlGF      /      mice, LPS resulted in a further 
increase in the expression of ICAM-1 and P-selectin but no 
demonstrable change in VCAM-1, E-selectin, or PAI-1. In 
addition, COX-2 was up-regulated in CD31-negative cells 
in the lumen of veins. Together with the real-time PCR data, 
these fi  ndings demonstrate that PlGF defi  ciency results in vas-
cular bed  –  specifi  c changes in the expression of infl  ammatory 
and coagulation markers, with the most widespread changes 
occurring in the liver. 
  PlGF defi  ciency results in liver dysfunction 
and leukocyte infi  ltration 
  The results described in the previous three sections suggest 
that PlGF defi  ciency is associated with disproportionate 
endotoxemia-mediated changes in the liver, including sustained 
elevation of VEGF, increased permeability, and higher ex-
pression of activation markers. Based on these fi  ndings, we 
wished to further explore the eff  ect of PlGF defi  ciency on 
the liver phenotype. Alanine aminotransferase, a measure of 
liver damage, was increased in PlGF      /      versus wild-type 
controls (wild-type, 63.3   ±   35.1 U/liter; PlGF      /     , 223.3   ±   
92.9 U/liter;   Fig. 5 A  ).   Moreover, endotoxemia resulted in 
    Figure 5.         Effect of PlGF defi  ciency on liver phenotype in a mouse 
model of endotoxemia.   PLGF +/+   (WT) or PLGF     /     (KO) male mice were 
injected i.p. with or without 16 mg/kg LPS. (A) Blood samples were taken 
at 24 h and assayed for plasma levels of alanine aminotransferase (ALT). 
(B) The liver was removed at 24 h and assayed for MPO activity. (C) The 
liver was removed at 24 h and stained for CD45. Data in A and B are ex-
pressed as means + SD of three independent experiments. *, P   <   0.05; 
**, P   <   0.01; and ***, P   <   0.0001 compared with untreated controls (and 
where indicated between PlGF-defi  cient and wild-type mice. Bar, 50   μ  m.     
    Figure 6.         Additional survival studies in mouse models of sepsis.   Male  PLGF +/+   (WT) or PLGF     /     mice were injected with Ad overexpressing GFP (GFP-ad) 
or PlGF (PlGF-ad; A), VEGF (VEGF-ad; B), or sFlt-1 (sFlt-ad; C). 3 d later, the animals were administered saline (control) or LPS i.p. and monitored for survival.    JEM VOL. 205, October 27, 2008 
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the same cell, may form PlGF/VEGF heterodimers (  40, 41  ). 
PlGF/VEGF heterodimers, in turn, have been shown to inhibit 
VEGF signaling (  41  ). In response to LPS, we found the ma-
jority of PlGF up-regulation in perivascular cells. Perivascu-
lar cells have also been shown to express VEGF (  42  ). Thus, 
it is tempting to speculate that the loss of PlGF yields not only 
elevated levels of free VEGF but also increased homodimer-
ization and, thus, bioactivity of VEGF. 
  The prevailing view in the literature is that PlGF functions 
as a proinfl  ammatory and permeability-enhancing cytokine. 
However, the results of the present study indicate that these 
eff  ects of PlGF are highly context dependent. For example, 
although PlGF induces vascular permeability in several skin 
models (  30, 31  ), it promotes barrier function in sepsis. PlGF 
has been shown to promote monocyte infi  ltration in ischemic 
tissues (  43  ), tumors (  26  ), atherosclerotic plaques (  27  ), and bone 
fractures (  24  ). However, as we have demonstrated in this pa-
per, PlGF inhibits leukocyte accumulation in the liver of sep-
tic animals. Previous studies have shown that PlGF up-regulates 
VEGF expression in wound or tumor stroma (  38, 39  ). More-
over, neutralizing anti-PlGF antibody failed to induce VEGF 
levels in the plasma in tumor-bearing mice (  26  ). In contrast, 
PlGF defi  ciency is clearly associated with increased VEGF lev-
els in sepsis. Additional studies will be needed to determine 
the precise mechanism by which PlGF signaling limits VEGF 
release and signaling under these conditions. 
  In summary, our fi  ndings suggest that the up-regulation of 
PlGF represents an adaptive host response to infection. As anti-
PlGF therapies become more widespread for the treatment of 
such conditions as cancer and atherosclerosis, it will be impor-
tant to carefully monitor patients for the development of in-
fections and systemic infl  ammatory response syndrome. 
  MATERIALS AND METHODS 
  Mice.     Mouse models of endotoxemia and CLP; measurement of IL-6, VEGF, 
sFlt-1, and PlGF in plasma; Ad-mediated overexpression of sFlt-1, VEGF, and 
PlGF; cardiac physiological studies; permeability assays; tissue RNA isolation; 
and real-time PCR were performed as previously described (  7  ). Unless other-
wise indicated in the fi  gures, all experiments were performed using 10  –  12-
wk-old FVB mice. All animal studies were approved by the Beth Israel 
Deaconess Medical Center Institutional Animal Care and Use Committee. 
  Survival studies.     Survival studies were performed using endotoxemia and 
CLP models. Survival was assessed at 24, 48, 72, and 96 h after 14  –  18 mg/kg 
body weight LPS injection or CLP. In studies involving adenoviral administra-
tion, the virus was injected 3 d before LPS administration. The same lot of LPS 
was used throughout the study. An LPS dose-response curve is shown in Fig. S3 
(available at http://www.jem.org/cgi/content/full/jem.20080398/DC1). 
  Antibody administration.     20 h before LPS or CLP administration, mice 
were injected i.p. with 1 mg anti  –  mouse PlGF-2 antibody (PL5D11D4) or 
the same dose of control antibody (1C8). The effi   cacy of this antibody has 
been previously reported (  26  ). 
  Immunohistochemistry.     Immunohistochemistry was performed using the 
following primary antibodies: hamster monoclonal anti  –  mouse ICAM-1 
(Serotec), rat monoclonal anti  –  mouse VCAM-1 antibody (BD Biosciences), rat 
monoclonal anti  –  mouse E-selectin antibody (BD Biosciences), rat monoclo-
nal anti  –  mouse P-selectin antibody (Millipore), rabbit polyclonal anti  –  mouse 
COX-2 antibody (Cayman Chemical), and rabbit polyclonal anti  –  mouse 
elevated circulating levels of PlGF in the PlGF-adenovirus 
(Ad)  –  treated mice (5,823.4   ±   833.6 pg/ml) did not confer a 
survival advantage over GFP-Ad (control)  –  injected wild-type 
animals. To determine whether PlGF defi  ciency rendered 
animals more sensitive to the eff  ects of VEGF, mice were in-
jected with control virus or VEGF-Ad and administered small 
doses of LPS (14 mg/kg). At the latter dose, 93.8% of wild-
type and PlGF      /      mice survived (  Fig. 6 B  ). However, over-
expression of VEGF (plasma levels, 4,204.5   ±   901.8 pg/ml) 
resulted in a marked increased in mortality in PlGF      /      com-
pared with wild-type animals (wild-type, 50% vs. PlGF      /     , 
100%) (  Fig. 6 B  ). Finally, the increased mortality associated 
with PlGF defi  ciency was reversed by overexpression of sFlt-1 
(  Fig. 6 C  ). Collectively, these results suggest that elevated 
VEGF levels are both suffi   cient and necessary to promote 
sepsis mortality in PlGF-defi  cient mice. 
    DISCUSSION   
  Compared with our understanding of VEGF, little is known 
about the function of PlGF. PlGF is thought to bind to 
VEGFR1/Flt-1 and the coreceptors neuropilin-1 and -2. The 
interaction between PlGF and VEGFR1/Flt-1 has been shown 
both to trigger downstream signaling and to enhance VEGF 
signaling via VEGFR2/Flk-1 (for review see reference   35  ). 
Although PlGF is not required for developmental angiogenesis, 
it appears to play an important role in postnatal angiogenesis, 
arteriogenesis, and vasculogenesis (  21  ). In addition, increasing 
evidence points to a proinfl  ammatory eff  ect of PlGF. Most no-
tably, PlGF-mediated induction of monocyte migration and 
activation has been shown to contribute to tumor growth (  26  ), 
atherosclerosis (  27  ), sickle cell disease (  25  ), and wound healing 
(  26  ). In addition, PlGF has been causally linked to vascular per-
meability and plasma extravasation (  21, 23, 28  –  31  ). 
  From a mechanistic standpoint, it has been proposed that 
PlGF displaces VEGF from VEGFR1/Flt-1, thus promoting 
VEGF  –  VEGFR2/Flk-1 interactions (  36  ). Moreover, PlGF-
mediated activation of VEGFR1/Flt-1 may lead to the trans-
activation of VEGFR2/Flk-1, further enhancing the response 
to VEGF (  37  ). Previous studies have revealed that PlGF up-
regulates the expression of VEGF by periendothelial fi  bro-
blasts, smooth muscle cells, or infl  ammatory cells in wound 
or tumor stroma (  38, 39  ). Together with our recent observa-
tions that sepsis is associated with elevated levels of VEGF 
and PlGF, and that VEGF plays a pathogenic role in sepsis (  7  ), 
these data led us to hypothesize that elevated levels of PlGF 
would accentuate sepsis morbidity and mortality. On the 
contrary, we found that PlGF plays a net protective role in 
mouse models of sepsis. 
  A clue to the mechanism by which PlGF defi  ciency causes 
increased morbidity and mortality was found in our discovery 
of elevated circulating VEGF levels in septic PlGF-defi  cient 
mice. Moreover, Ad-mediated expression of sFlt-1 reversed 
the excess mortality in LPS-treated PlGF      /      mice. Thus, the 
increased mortality associated with PlGF defi  ciency is attrib-
uted, at least in part, to exaggerated VEGF levels. Previous stud-
ies have demonstrated that PlGF and VEGF, when produced by 2630 P  L  GF AND SEPSIS   | Yano et al. 
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